Our History

2015

April 2015

Placing with new and existing institutional investors raises £40m before expenses, to invest further in RNA platform and delivery technologies.

February 2015

Board of Appeal of the European Patent Office upheld Silence’s key RNAi trigger modification patent against challenges by four parties including Alnylam, Sirna Therapeutics, Alcon Laboratories and an independent attorney.


2014

December 2014

Announced breakthrough in messenger RNA technology – successful production of potentially therapeutic levels of protein in vivo, in pre-clinical animal models

July 2014

Recruitment for Phase 2a trial of Atu027 in pancreatic cancer is completed on schedule

April 2014

Raised £11.4m through placing of new ordinary shares


2013

August 2013

Study of Atu027 in solid tumours enters Phase 2a.

Atu027

April 2013

Raised £18.025m through placing of new ordinary shares


2012

November 2012

Raised £5m through subscription of new ordinary shares and conversion of £1m loan note

November 2012

Two further patents awarded by US Patent Office for interfering RNA molecules and lipid complexes used in drug delivery

July 2012

Raised £5.45 million through a subscription, open offer and issue of a convertible loan note

May 2012

Quark Pharmaceuticals extends agreement with Pfizer to develop a compound containing Silence’s AtuRNAi in a new indication

quark

May 2012

Initial results from Phase 1 study of Atu027 in solid tumours demonstrate anti-tumour potential


2011

August 2011

US patent granted for AtuFECT, a core component of the AtuPLEX™ delivery platform

May 2011

Placing and open share offer raises £5.9m from new and existing investors


2010

September 2010

Two new patents granted by US Patent Office for siRNA sequences

August 2010

Silence’s partner Quark signs exclusive option agreement with Novartis for development and commercialisation of QPI-1002 (AtuRNAi) in two kidney indications. Silence receives US$1m with potential milestone payments

Novartis

2009

June 2009

Phase 1 study of lead drug Atu027 initiated in patients with advanced solid tumours


2008

November 2008

Core RNAi (AtuRNAi) patent granted in the US


2007

July 2007

siRNA research collaboration and license agreement signed with AstraZeneca for five targets. Silence receives US$15m and potential milestone payments

AstraZeneca

May 2007

SR Pharma changes its name to Silence Therapeutics plc

Silence Logo

January 2007

Core RNAi patent granted in Europe for AtuRNAi platform


2006

October 2006

Nobel Prize for Medicine granted to Andrew Fire and Craig Mello, for their discoveries relating to gene silencing

September 2006

Pfizer in-licensed first AtuRNAi preclinical programme from collaboration partner Quark Pharmaceuticals Inc. The Company receives US$3.5m with potential milestone payments

Pfizer

2005

July 2005

The Company in its current form is created when Atugen completes reverse takeover of SR Pharma plc, listed on London’s AIM. Fundraising of GBP10m mainly from institutional UK investors

SR Pharma plc

2002

February 2002

First core RNAi (AtuRNAi) patent application filed in Germany


2000

January 2000

Further funding by Apax (€10m) and MPM Capital (€5m)


1999

January 1999

Atugen AG founded as a spin-off from Ribozyme Pharmaceuticals Inc. (later renamed Sirna Therapeutics Inc.) funded by MPM Capital (US$7m). Focus on target discovery and validation collaborations with leading pharmaceutical companies using proprietary antisense and delivery technologies

Atugen